Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Doxorubicin in Advanced Sarcoma
NCT02888665Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in soft tissue sarcoma (STS), sponsored by Fred Hutchinson Cancer Center. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02888665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888665.